Clinical evaluation of DAREN® in the prophylactic treatment of Japanese cedar pollinosis

Abstract

A comparative study was performed for the purpose of studying the prophylactic effectiveness of an antecedent treatment for Japanese cedar pollinosis with DAREN® (emedastine difumarate), an anti-allergic drug. Thirty-five cases (A group) received the drug at drug at 4 mg/day at least 2-4 weeks before the day when the pollen began to scatter. Another thirty-nine patients received the treatment after the scattering (B group). A significant inter group difference was observed in the global improvement rate for pollinosis. These findings suggest that DAREN® produces a slow, long-acting effect such as the inhibition of the release of chemical mediators. Prophylactic medication seems to be suitable for the treatment of Japanese cedar pollinosis, because sufficient anti-allergic action is obtained a few weeks later. Side effects occurred in 6.9% of all of the cases, but the incidence was lower than with any other anti-allergic drug previously reported. In summary, a prophylactic treatment with DAREN® is effective in treating Japanese cedar pollinosis.